Akeso, Inc. (HKG:9926)
Hong Kong
· Delayed Price · Currency is HKD 84.35
+0.10 (0.12%)
May 9, 2025, 4:08 PM HKT
Akeso Employees
Akeso had 2,778 employees as of December 31, 2023. The number of employees increased by 437 or 18.67% compared to the previous year.
Employees
2,778
Change (1Y)
437
Growth (1Y)
18.67%
Revenue / Employee
744.73K HKD
Profits / Employee
-180.41K HKD
Market Cap
75.71B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2,778 | 437 | 18.67% |
| Dec 31, 2022 | 2,341 | 476 | 25.52% |
| Dec 31, 2021 | 1,865 | 1,119 | 150.00% |
| Dec 31, 2020 | 746 | 356 | 91.28% |
| Dec 31, 2019 | 390 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BeiGene | 11,000 |
| Hansoh Pharmaceutical Group Company | 8,989 |
| JD Health International | 3,564 |
| WuXi Biologics | 12,575 |
| Innovent Biologics | 5,659 |
| Alibaba Health Information Technology | 1,435 |
| Sichuan Kelun-Biotech Biopharmaceutical | 1,837 |
| Sino Biopharmaceutical | 24,379 |
Akeso News
- 11 days ago - Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
- 11 days ago - China’s Akeso, hailed as biotech’s ‘DeepSeek moment’, falls despite nod for cancer drug - South China Morning Post
- 14 days ago - What's Going On With Summit Therapeutics Stock On Friday? - Benzinga
- 16 days ago - Why Is Summit Therapeutics Stock Soaring On Wednesday? - Benzinga
- 18 days ago - Akeso (9926) Poised for Growth Despite Current Undervaluation - GuruFocus
- 19 days ago - Bullish On Akeso's Ivonescimab, But Valuation And Geopolitical Risks Remain - Seeking Alpha
- 4 weeks ago - Why This Chinese Biotech Could Be Pharma's DeepSeek - Benzinga
- 5 weeks ago - Akeso reports FY results - Seeking Alpha